Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 |
| 30 Jun 2025 |
| Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide | 18 Jun 2025 |
| Zealand Pharma increases its share capital as a result of the exercise of employee warrants | 6 Jun 2025 |
| Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | 27 May 2025 |
| Zealand Pharma announces closing of collaboration and license agreement with Roche | 9 May 2025 |